{"schema_version":"1","generated_at":"2026-11-20T20:53:22.042Z","data_as_of":null,"url":"https://www.findmykol.com/kol/thomas-pressly","json_url":"https://www.findmykol.com/kol/thomas-pressly/profile.json","record_kind":"basic","profile_kind":"clinical","person":{"slug":"thomas-pressly","name":"Thomas Pressly","credential":"MD","specialty":"Rheumatology","specialty_raw":"Rheumatology","therapeutic_area":"Rheumatology/Immunology","therapeutic_areas":["Rheumatology/Immunology"],"institution":"Shriners Hospitals for Children - Shreveport","institution_url":"https://www.findmykol.com/institution/shriners-hospitals-for-children-shreveport","city":"Shreveport","state":"LA","region":{"label":"South Central","url":"https://www.findmykol.com/region/south-central"}},"identifiers":{"on_file":["npi","openalex"],"values":"Shown on the profile page to a signed-in account."},"summary":"Thomas Pressly is a Rheumatology/Immunology physician affiliated with Shriners Hospitals for Children - Shreveport. OpenAlex indexes 23 publications with 648 citations (h-index 13).","overview":null,"focus":{"indications":[],"research_topics":["Rheumatology/Immunology"]},"scholarship":{"works_count":23,"cited_by_count":648,"h_index":13,"latest_activity_year":2025,"source":"works"},"payments":{"company_count":19,"program_years":{"first":2021,"last":null},"rows_total":57,"shown":3,"withheld":54,"rows":[{"payer":"AbbVie","program_year":2025,"amount_usd":11676.8,"payment_count":6},{"payer":"Amgen Inc.","program_year":2025,"amount_usd":372.53,"payment_count":15},{"payer":"ABBVIE INC.","program_year":2025,"amount_usd":310.3,"payment_count":16}],"source":"payments"},"prescribing":{"data_year":2023,"areas_total":10,"areas_shown":3,"areas":[{"area":"Nervous system","share_pct":27.7,"classes_total":9,"classes":[{"class":"Gabapentinoids","setting":"prescribed","share_pct":10.7,"drugs":[{"name":"Gabapentin","share_pct":81.8},{"name":"Pregabalin","share_pct":18.2}],"max_beneficiaries":99},{"class":"Nonsteroidal Anti-inflammatory Drug","setting":"prescribed","share_pct":5.4,"drugs":[{"name":"Meloxicam","share_pct":100}],"max_beneficiaries":64}]},{"area":"Cancer & immunology","share_pct":20.4,"classes_total":8,"classes":[{"class":"Folate Analog Metabolic Inhibitor","setting":"prescribed","share_pct":12.4,"drugs":[{"name":"Methotrexate","share_pct":97.5},{"name":"Methotrexate Sodium","share_pct":2.5}],"max_beneficiaries":122},{"class":"TNF inhibitor","setting":"prescribed","share_pct":2.9,"drugs":[{"name":"Enbrel","share_pct":43.3},{"name":"Humira(Cf) Pen","share_pct":31.3},{"name":"Humira(Cf)","share_pct":16},{"name":"Humira","share_pct":9.3}],"max_beneficiaries":null}]},{"area":"Metabolism & gastrointestinal","share_pct":20,"classes_total":5,"classes":[{"class":"Corticosteroid","setting":"prescribed","share_pct":18.3,"drugs":[{"name":"Prednisone","share_pct":100}],"max_beneficiaries":144},{"class":"Proton pump inhibitor","setting":"prescribed","share_pct":0.7,"drugs":[{"name":"Omeprazole","share_pct":100}],"max_beneficiaries":null}]}],"care_setting":{"dominant":"office","data_year":2023,"office_pct":100,"facility_pct":0},"source":"medicare"},"publications":{"total":23,"shown":5,"withheld":18,"matched_by":"OpenAlex author record","recent":[{"title":"Alendronate for the Treatment of Pediatric Osteogenesis Imperfecta: A Randomized Placebo-Controlled Study","year":2010,"journal":"The Journal of Clinical Endocrinology & Metabolism","source_url":"https://doi.org/10.1210/jc.2010-0636","status":"verified"},{"title":"Neurosarcoidosis","year":2008,"journal":"American Journal of Therapeutics","source_url":"https://doi.org/10.1097/mjt.0b013e31818637ef","status":"verified"},{"title":"Soluble HLA: patterns of expression in normal subjects, autoimmune diseases, and transplant recipients","year":2005,"journal":"Rheumatology International","source_url":"https://doi.org/10.1007/s00296-005-0585-y","status":"verified"},{"title":"Soluble HLA-I (s-HLA-I) synthesis in systemic lupus erythematosus","year":2003,"journal":"Rheumatology International","source_url":"https://doi.org/10.1007/s00296-003-0306-3","status":"verified"},{"title":"Soluble HLA in saliva of patients with autoimmune rheumatic diseases","year":2002,"journal":"Rheumatology International","source_url":"https://doi.org/10.1007/s00296-002-0173-3","status":"verified"}],"source":"works"},"similar":[{"name":"Cary Mielke","slug":"cary-mielke","institution":"Shriners Hospitals for Children - Shreveport","specialty":"Orthopaedic Surgery","url":"https://www.findmykol.com/kol/cary-mielke","json_url":"https://www.findmykol.com/kol/cary-mielke/profile.json"},{"name":"Philip Gates","slug":"philip-gates","institution":"Shriners Hospitals for Children - Shreveport","specialty":"Orthopaedic Surgery","url":"https://www.findmykol.com/kol/philip-gates","json_url":"https://www.findmykol.com/kol/philip-gates/profile.json"},{"name":"David Felson","slug":"david-felson","institution":"Boston University","specialty":"Rheumatology","url":"https://www.findmykol.com/kol/david-felson","json_url":"https://www.findmykol.com/kol/david-felson/profile.json"},{"name":"Marc Hochberg","slug":"marc-hochberg","institution":"University of Maryland School of Medicine","specialty":"Rheumatology","url":"https://www.findmykol.com/kol/marc-hochberg","json_url":"https://www.findmykol.com/kol/marc-hochberg/profile.json"},{"name":"Philip Mease","slug":"philip-mease","specialty":"Rheumatology","url":"https://www.findmykol.com/kol/philip-mease","json_url":"https://www.findmykol.com/kol/philip-mease/profile.json"},{"name":"Michelle Petri","slug":"michelle-petri","institution":"Johns Hopkins University School of Medicine","specialty":"Rheumatology","url":"https://www.findmykol.com/kol/michelle-petri","json_url":"https://www.findmykol.com/kol/michelle-petri/profile.json"}],"coverage":{"note":"A basic directory record. Sections absent here were not yet checked for this person, so absence means not yet looked, never none found.","not_yet_checked":["funding","congress","network","presence","recognition"]},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"payments":54,"publications":18}},"sources":{"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 onward"},"medicare":{"name":"CMS Medicare Part D Prescribers and Part B","url":"https://data.cms.gov/provider-summary-by-type-of-service","provides":"Share of this prescriber's Medicare fee-for-service prescribing by drug class and therapeutic area, classified with WHO ATC and NLM RxClass","disclaimer":"Proportions of the prescriber's own classified prescribing, never patient counts or dollar amounts. Fee-for-service only; CMS publishes about 17 months after the fact and suppresses counts of ten patients or fewer.","data_year":2023}},"methodology_url":"https://www.findmykol.com/about#methodology"}